I listened to the presentation today by Scott. Nothing new except for a clearer presentation of the science behind 427 which was helpfull. There was an indication from materials that interim data should be comming soon from 427. Will this be enough to start some kind of positive price action for this name which has been in the penalty box since the last financing? The shorts have been steadily reducing their exposure which is often a tell with junior biotechs. This name has the potential to be mid single digits or low triple digits in 24 months so the question is worthy of discussion.
I start with the premise that I don't know. I use to think it would go up as 011 was ready for read out. Or 427 Phase II read out or partnership announcement would trigger accretion. My estimate now is that it will slowly go up but not wildly and we have to wait to reap real benefits after 011 is approved. I hope I am wrong.